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Abstract
Background: Alkaline phosphatase (ALP) is a widely used
marker for skeletal and hepatobiliary disorders, but its activ-
ity is also increased in atherosclerosis and peripheral vascular
disease. It is an inflammatory marker like C-reactive protein
(CRP). We therefore analyzed its relationship with CRP in
the United States National Health and Nutrition Examination
Survey (NHANES) 2005–2006.
Methods: The analysis included 4155 men and non-pregnant
women over the age of 20 years. The relationship between
log-transformed ALP and plasma CRP was analyzed using
univariate and multivariate models.
Results: ALP activity was significantly correlated with age,
waist circumference, body mass index, blood pressure,
exercise, alcohol, triglycerides, and other liver enzymes
after adjusting for age, gender and ethnicity (p-0.001). ALP
was significantly associated with a higher frequency of
cardiovascular disease (ps0.02), hypertension (ps0.01)
hypercholesterolemia (ps0.04), and diabetes (ps0.02).
Compared to the lowest quartile of ALP, the adjusted odds
ratio (OR) associated with the highest quartile were 1.9 w95%
confidence intervals (CI) 1.1–3.5x, 1.6 (95% CI 1.0–2.5), 1.5
(95% CI 1.1–2.1) and 1.7 (95% CI 1.0–2.4) for cardiovas-
cular disease, hypertension, hypercholesterolemia, and dia-
betes, respectively. In multivariate analysis, log ALP was an
independent predictor of log CRP (ps1.0=10y6). A mul-
tivariate model that included log ALP, ethnicity, glycohe-
moglobin, waist circumference, albumin, apolipoprotein B,
g-glutamyltransferase and uric acid explained 40% of the
variance in log CRP.
Conclusions: ALP is a marker of cardiometabolic risk, but
it needs to be tested as part of a multivariate model in pro-
spective studies.
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Introduction
According to the World Health Organization, ;17 million
people every year die from cardiovascular events, particu-
larly myocardial infarction and stroke (1). Arterial inflam-
mation has recently emerged as a central pathophysiological
mechanism in the development and progression of athero-
sclerotic disease, and plays a major role in adverse cardio-
vascular outcomes (2–4). During the process of
atherosclerosis, there is an accumulation of inflammatory
cytokines and activation of the acute phase response, leading
to the release of C-reactive protein (CRP) from the liver (5).
CRP is widely used and an easily measured biomarker of
systemic inflammation and is also known to be a powerful
indicator of cardiovascular risk (6–9). In obesity, there is an
increase in CRP concentrations. Numerous cross-sectional
epidemiological studies have demonstrated a correlation
between CRP concentrations and multiple variables related
to cardiovascular disease and the metabolic syndrome
(10–12). It is also known that increased CRP concentrations
can predict adverse outcomes in patients with angina (6, 13)
and peripheral vascular disease (12).
Alkaline phosphatase (ALP) belongs to a group of ubiqui-
tous metalloenzymes that catalyze the hydrolysis of mono-
phosphate esters at alkaline pH, but its exact physiologic
function is unknown. ALP is routinely used in the diagnosis
and follow-up of osteoporosis and hepatobiliary disorders
since it originates from bone and liver. ALP can also be
found to a lesser extent in the intestines, kidneys and the
placenta (14). Regan and Nagao, isoenzymes of ALP that
are present in the placenta and in neoplastic lesions, respec-
tively, are used in analysis during gestation and in non-phys-
iologic conditions. ALP is also found in white blood cells
including neutrophils, eosinophils, and basophils of many
species, including humans, horses, and cattle. ALP is
increased in the metabolic syndrome and correlates with
plasma CRP concentrations (2, 15, 16). In an epidemiolog-
ical study in Hong Kong Chinese, ALP was related to a
number of other identifiable risk factors (16). In men, plasma
ALP was significantly higher in patients with diabetes and
in those who smoked. In women, plasma ALP was signifi-
cantly related to age, body mass index (BMI), systolic blood
pressure (BP), diabetes, triglyceride concentrations and
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menopausal status (16). High serum activities of ALP have
also been noted in patients with peripheral arterial disease
(PAD) (17). PAD is a systemic vascular disease, associated
with widespread arterial atherosclerosis and vascular
inflammation.
Its correlation with CRP, inflammation, obesity, and ath-
erosclerosis makes ALP a potential diagnostic marker or pre-
dictor of cardiovascular disease. At present, there are only a
limited number of small scale studies on this aspect of ALP.
Therefore, we analyzed the relationship between ALP and
CRP in a large representative population.
Materials and methods
Study population
For our analysis, data were extracted from the open database of the
United States National Health and Nutrition Examination Survey
2005–2006 (NHANES 2005–2006). This is part of a continuous
group of studies designed to provide health and nutritional infor-
mation for adults and children in the USA (18). All participants
gave informed consent prior to examination, and the survey was
approved by the National Center for Health Statistics, specifically
the Center for Disease Control and Prevention Institutional Review
Board Program. Participants were examined in well equipped
mobile examination centers located around the USA. Examinations
were standardized according to the environment, equipment used
and specimen collection. Participants were selected using a complex
stratified sample design, which included members of the civilian,
non-institutionalized USA population. All individuals were assigned
a numerical weight to account for variations in response and un-
equal selection probabilities. The selection process included over-
sampling of subgroups of special interest, such as African
Americans, Mexican Americans, adolescents, low-income individ-
uals, and people aged G60 years. Among the 10,348 participants
eligible for inclusion, 9860 had their serum ALP, alanine amino-
transferase (ALT), aspartate aminotransferase (AST), g-glutamyl-
transferase (GGT) and CRP measured. We then excluded 5369
participants under the age of 20 years, 57 of whom were pregnant,
and 336 pregnant women who were aged 20 years or older. There-
fore, 4155 participants were included in our analysis.
Variables of interest
Demographic variables including age, race/ethnicity, and pregnancy
status were based on a ‘Sample Person and Family Demographics’
questionnaire, completed by participants prior to physical exami-
nation. Pregnancy status was determined by testing urine. The pop-
ulation was classified into ethnic subgroups including Mexican
American, other Hispanic, non-Hispanic whites, non-Hispanic
blacks, and others. Smoking, alcohol intake, physical activity, and
cardiovascular disease status were also based on self-reported ques-
tionnaires. For the purpose of our analysis, alcohol intake was
defined as consuming at least one alcoholic drink a week during
the past year. Smokers were defined as participants who smoked
100 or more cigarettes in their lifetime. Physical activity was
defined as taking part in moderate to vigorous levels of activity at
least once a month.
Waist circumference, weight and BP were obtained by trained
personnel in the Mobile Examination Centers. Weight was taken
using a Toledo digital scale, recorded in pounds and later converted
to kilograms. BMI was calculated as the weight (kg) divided by the
square of the height (m). BP was measured by a certified NHANES
physician using a calibrated mercury manometer and a Littmann
cardiology stethoscope.
History of cardiovascular disease, namely, coronary heart disease,
congestive heart failure, angina, stroke and myocardial infarction,
was obtained from self-reported questionnaires. Diabetes was
defined as being diagnosed with diabetes by a physician at some
point in one’s lifetime, currently taking insulin, having a resting
plasma glucose concentration )200 mg/dL (11.1 mmol/L), or a
fasting glucose of )126 mg/dL (7.0 mmol/L). Hypercholesterole-
mia was defined as diagnosis by a doctor, currently taking choles-
terol lowering medication, or having a total serum cholesterol
G240 mg/gL (6.2 mmol/L). Hypertension was defined as diagnosis
by a doctor, currently taking BP lowering medication or having a
resting BP G140/90 mm Hg.
Laboratory measurements
Plasma CRP was measured in participants using a latex enhanced
nephelometric method. Glycohemoglobin was measured using an
assay for SA1c and La1c (two forms of glycated hemoglobin) which
were individually resolved using a chromatogram and analyzed
using a Tosoh Alc 2.2 Plus Glycohaemoglobin Analyzer (Tosoh
Meics, Inc, San Francisco, CA, USA). High-density lipoprotein
(HDL) and low-density lipoprotein (LDL) cholesterol were meas-
ured in the blood using either a Hitachi 717 or Hitachi 912 analyzer
(Roche, formerly Boehringer-Mannheim Diagnostics, Indianapolis,
IN, USA). Albumin concentrations were measured using a bichro-
matic digital endpoint method. Serum ALP, ALT, AST, and GGT
activities were determined with a Beckman Synchron LX20 analyz-
er (Beckman Coulter Inc., Fullerton, CA, USA). The adult reference
range for ALP in NHANES is 36–113 U/L. Triglycerides were
measured using a Hitachi 717 analyzer, glucose by use of a rate
method utilizing a Beckman oxygen electrode and apolipoprotein B
by means of a Dade Behring BN100 Nephelometer (Dade Behring
Diagnostics Inc., Somerville, NJ, USA). Samples for ALP and CRP
analysis that were not assayed within 48 h were frozen and thawed
only once to avoid analyte degradation and abnormal over expres-
sion. A more detailed explanation of the study design, interview
techniques, measurement procedures, and protocol is given on the
NHANES website (18).
Statistical analysis
Data from the 4155 participants were analyzed using the complex
sampling function of SPSS version 17.0 for Apple Macintosh (SPSS
Inc, Chicago, IL, USA), to take into account the oversampling used
in the NHANES 2005–2006 study. MEC examination weights were
used in all analyses to adjust for oversampling and non-response
bias. Variables that had a skewed distribution were log transformed
in all correlation and regression analysis. Partial bivariate correlation
was performed to analyze the relationship between CRP, ALP and
other variables while adjusting for age, gender and ethnicity. p-
Values were obtained using linear regression or logistic regression
analysis where appropriate, using the complex samples function.
Multiple linear regression was used to identify independent
variables, including log ALP, that were related to log CRP. Variables
that showed significant correlation with CRP in bivariate analysis
were entered stepwise. A variable was retained if it was indepen-
dently associated with log CRP (p-0.05). Serum ALP was cate-
gorized into quartiles according to the weighted distribution in the
sample. The association of serum ALP activity with cardiovascular
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Table 1 Characteristics of the study participants.
Male (ns2147) Female (ns2008) Combined (ns4115)
Age, years 46.1"0.8 48.2"0.7 47.2"0.7
Race/ethnicity
Mexican American 8.8"1.2 6.8"0.8 7.8"1.0
Other Hispanic 3.2"0.9 3.4"0.7 3.3"0.8
Non-Hispanic white 73.2"2.7 72.5"2.8 72.8"2.7
Non-Hispanic black 10.4"1.7 11.6"2.1 11.0"1.9
Others 4.5"0.6 5.7"0.8 5.1"0.6
Waste circumference, cm 101.4"0.7 94.1"0.8 97.7"0.7
Weight, kg 89.0"0.8 75.1"0.9 81.9"0.7
BMI, kg/m2 28.6"0.3 28.6"0.3 28.6"0.3
Blood pressure
Systolic BP, mm Hg 123.0"0.5 120.7"0.8 121.9"0.6
Diastolic BP, mm Hg 71.5"0.5 69.1"0.5 70.3"0.4
Exercise, % 68.1"2.1 66.2"1.4 67.1"1.5
Smokers, %
Never 43.5"1.8 57.4"1.5 50.6"1.4
Former 28.8"1.3 21.5"1.0 25.1"1.0
Current 27.7"1.6 21.1"1.3 24.3"1.2
Alcohol drinking, % 40.1"1.6 21.7"1.6 30.7"1.5
Cardiovascular disease, % 9.4"0.8 8.3"0.9 8.8"0.6
Hypertension, % 35.1"1.2 35.5"1.5 35.3"1.1
Diabetes, % 11.1"0.9 11.0"0.9 11.0"0.7
Hypercholesterolemia, % 38.5"1.6 38.1"1.7 38.3"1.4
Total cholesterol, mmol/L 5.1"0.03 5.3"0.02 5.2"0.02
LDL, mmol/L 3.01"0.04 2.97"0.04 2.99"0.03
HDL, mmol/L 1.3"0.008 1.5"0.02 1.4"0.0005
Apolipoprotein B, g/L 1.04"0.01 0.99"0.02 1.01"0.01
Triglycerides, mmol/La 1.56 (1.51–1.63) 1.42 (1.38–1.46) 1.42 (1.39–1.46)
Albumin, g/L 43.0"0.1 42.0"0.2 42.0"0.1
Glucose, mmol/La 5.4 (5.3–5.42) 5.3 (5.2–5.4) 5.4 (5.3–5.5)
Glycohemoglobin, %a 5.3 (5.4–5.5) 5.4 (5.4–5.5) 5.4 (5.4–5.5)
Uric acid, nMa 350.9 (350.9–356.9) 279.6 (273.6–279.6) 321.2 (303.3–321.2)
ALP, U/La 66.7 (65.5–68.1) 64.6 (62.9–67.1) 66.1 (64.6–67.6)
ALT, U/La 26.8 (26.2–27.5) 23.0 (22.5–23.5) 22.9 (22.4–23.4)
AST, U/La 26.0 (25.5–26.6) 24.2 (23.8–24.6) 24.6 (24.0–24.5)
GGT, U/La 26.1 (25.0–27.3) 21.5 (20.8–22.3) 21.4 (20.9–22.4)
CRP, mg/La 1.6 (1.5–1.8) 2.1 (1.9–2.4) 1.8 (1.7–2.0)
Data are expressed as mean or percentage"standard error. aFor data with a skewed distribution, the geometric mean (95% CI) is given.
BMI, body mass index; BP, blood pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein; ALP, alkaline phosphatase; ALT,
alanine aminotransferase; AST, aspartate aminotransferase; GGT, g-glutamyltransferase; CRP, C-reactive protein.
disease, hypertension and diabetes was then assessed using ALP
quartiles as a categorical variable in multiple logistic regression.
Results
Table 1 shows the characteristics of all study participants
according to gender. Compared to women, men had a greater
waist circumference, weight, systolic and diastolic BP, and
higher ALP, plasma LDL and triglycerides, but lower total
cholesterol and CRP concentrations. Also, men were more
likely to drink alcohol, smoke cigarettes and suffer from car-
diovascular disease.
Table 2 shows the partial bivariate correlation between
log-transformed ALP and CRP with other variables after
adjusting for gender, age and ethnicity (Mexican American,
other Hispanic, non-Hispanic white, non-Hispanic black, and
other). In men, log ALP was significantly correlated with
age, waist circumference, BMI, BP, smoking, alcohol intake,
HDL, albumin, glycohemoglobin, ALT, AST and GGT. Log
CRP was correlated to all the aforementioned variables as
well as with weight, exercise, plasma triglycerides, glucose
and uric acid. In women, log ALP and log CRP were sig-
nificantly correlated with age, waist circumference, weight,
BMI, BP, exercise, smoking, alcohol intake, total cholesterol,
LDL, HDL, apolipoprotein B, triglycerides, albumin, glu-
cose, uric acid, ALT and GGT. Log ALP was significantly
correlated with CRP after controlling for gender, age, and
ethnicity (rs0.28, p-0.001).
Table 3 shows the results of stepwise multiple linear
regression analysis. The model was adjusted for gender, age,
ethnicity, hypertension, hypercholesterolemia, triglycerides,
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Table 2 Correlation between ALP and CRP with other variables of interest.
ALP, log U/L CRP, log mg/L
Male Female Combined Male Female Combined
Age, years 0.08 0.24 0.17 0.23 0.51 0.16
Waist circumference, cm 0.08a 0.24 0.15 0.41 0.51 0.47
Weight, kg – 0.21 0.08 0.36 0.47 0.42
BMI, kg/m2 0.07a 0.24 0.13 0.39 0.50 0.45
Systolic BP, mm Hg 0.08b 0.16 0.12 0.13 0.13 0.12
Diastolic BP, mm Hg 0.08a 0.15 0.10 0.12 0.07b 0.10
Exercise, % – –0.11 –0.07 –0.11 –0.13 –0.12
Smokers, % 0.04b 0.07b 0.03a 0.05a 0.06a 0.06
Alcohol drinking, % –0.12b –0.14 –0.14 –0.07a –0.13 –0.10
Total cholesterol, mmol/L – 0.10 0.06 – 0.11 0.07
LDL, mmol/L – 0.08b – – –0.10 –
HDL, mmol/L –0.06b –0.15a –0.09 –0.22 –0.25 –0.24
Apolipoprotein B, g/L – 0.11 0.07a – 0.24 0.15
Triglycerides, mmol/Lc – 0.17 0.13 0.14 0.30 0.21
Albumin, g/L –0.17 –0.13a –0.15 –0.34 –0.40 –0.37
Glucose, mmol/Lc – 0.14 0.12 0.13 0.20 0.17
Glycohemoglobin, %c 0.09a 0.19 0.14 0.19 0.24 0.22
Uric acid, nMc – 0.10 0.03 0.20 0.25 0.22
ALP, U/Lc – – – 0.24 0.33 0.28
ALT, U/Lc 0.09a 0.23 0.17 0.12b 0.11 0.10
AST, U/Lc 0.12a 0.17 0.22 – – –
GGT, U/Lc 0.29 0.37 0.35 0.27 0.35 0.30
CRP, mg/Lc 0.24 0.33 0.28 – – –
Partial correlation coefficients were calculated using sample weights and adjusted for age (except in age specific estimates), gender (except
of gender specific estimates) and ethnicity (Mexican American, other Hispanic, non-Hispanic white, non-Hispanic black, and other). ap-0.01;
bp-0.05. p-0.001 for all other correlation coefficients. cData were log transformed in assessing p due to their skewed distribution. Non-
significant values were omitted. BMI, body mass index; BP, blood pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein;
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, g-glutamyltransferase; CRP, C-reactive
protein.
Table 3 Multivariate linear regression analysis of independent predictors of log CRP, mg/L.
Male (ns2147) Female (ns2008) Combined (ns4155)
Regression p-Value Regression p-Value Regression p-Value
coefficient coefficient coefficient
ALP, U/La 0.56 1.51=10y4 0.57 1.60=10y4 0.57 1.01=10y6
Glycohemoglobin, %a – – 0.03 0.07 0.34 4.45=10y4
Waist circumference, cm 0.009 1.79=10y7 0.01 3.46=10y7 0.01 1.06=10y9
Albumin, g/L –0.043 1.68=10y5 –0.049 7.15=10y7 –0.047 3.39=10y8
Apolipoprotein B, g/L – – 0.3 0.001 0.2 0.003
GGT, U/L 0.23 0.003 0.31 0.002 0.26 0.001
Uric acid, nmol/La 1.68=10y5 3.60=10y4 1.68=10y5 0.25 1.68=10y5 2.45=10y4
R2 0.36 – 0.43 – 0.40 –
aData were log transformed in assessing p for trend due to their skewed distribution. The model was adjusted for gender, age, ethnicity
(Mexican American, other Hispanic, non-Hispanic white, non-Hispanic black, others), smoking, hypertension, hypercholesterolemia, ALTa,
and triglyceridesa. ALP, alkaline phosphatase; GGT, g-glutamyltransferase; ALT, alanine aminotransferase.
glycohemoglobin, and ALT. Independent predictor variables
of CRP included ALP, glycohemoglobin, waist circumfer-
ence, albumin, apolipoprotein B, GGT, and uric acid. In men,
ALP, waist circumference, albumin, GGT, and uric acid were
predictors. In women, ALP, glycohemoglobin, waist circum-
ference, albumin, apolipoprotein B and GGT were predictors.
ALP was a highly significant predictor of plasma CRP
(ps1.0=10y6). The full model explained 40% of the vari-
ance in log CRP. ALP remained a significant independent
predictor of CRP (ps2.0=10y6) after excluding 152 partic-
ipants who had a self-reported history of liver disease.
Table 4 shows the frequencies (%) of cardiovascular
disease, hypertension, hypercholesterolemia and diabetes
according to ALP quartiles. ALP was significantly associated
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Table 4 History of cardiovascular disease, hypertension, diabetes, and hypercholesterolemia according to quartiles of serum ALP, U/L.
Characteristics Quartile 1 Quartile 2 Quartile 3 Quartile 4 p for trend
(-56) (56–68) (68–83) (G84)
n 1115 1033 998 1009
Cardiovascular disease, % 5.6"0.7 7.6"1.0 9.6"1.1 14.4"2.3 0.02
Hypertension, % 20.1"1.5 23.5"0.9 27.9"1.3 36.5"3.0 0.01
Diabetes, % 7.5"1.0 8.9"1.0 13.3"0.9 16.7"1.1 0.02
Hypercholesterolemia, % 30.5"2.1 39.4"2.0 40.7"1.7 46.0"2.5 0.04
Data are expressed as mean percentage"standard error. ALP was log transformed due to its skewed distribution. p-Values were derived
from multiple logistic regression after adjusting for age, gender and ethnicity (Mexican American, non-Hispanic white, non-Hispanic black,
other Hispanic and others). ALP reference range: (36–113 U/L).
with cardiovascular disease (ps0.02), hypertension (ps
0.01) hypercholesterolemia (ps0.04), and diabetes
(ps0.02) after adjusting for age, gender, ethnicity and BMI
in a multiple logistic regression model. Compared to the low-
est quartile of ALP, the highest quartile of ALP had a higher
odds of cardiovascular disease wodds ratio (OR)s1.9, 95%
confidence intervals (CI) 1.1–3.5x, hypertension (ORs1.58,
95% CI 1.0–2.5), hypercholesterolemia (ORs1.5, 95% CI
1.1–2.1) and diabetes (ORs1.6, 95% CI 1.0–2.4).
We repeated the analysis using NHANES 2004–2005 data
and obtained similar results; serum ALP was also signifi-
cantly related to CRP (data not shown).
Discussion
This is the first study of its size to report a significant asso-
ciation between the blood levels of ALP and CRP. Our study
is consistent with previous reports showing increased ALP
activity relating to metabolic syndrome risk factors and car-
diovascular disease (16, 19).
In a previous study on Chinese individuals, the association
between ALP and CRP was only significant in women (16).
In NHANES, the association was similar in men and women.
Whether the discrepancy was due to sample size or ethnicity
requires further investigation. The relationship between CRP
and ALP is consistent with epidemiological studies reporting
the association between liver markers and the metabolic syn-
drome (2, 15). It has been reported in numerous cross-sec-
tional studies that CRP is a predictor of cardiovascular
disease (8–10, 20, 21). Like CRP, ALP is increased in non-
alcoholic fatty liver disease and in the metabolic syndrome
(2, 15), which are known to be risk factors for atherosclerosis
and cardiovascular disease (22).
Apart from CRP, we found that ALP was also correlated
with other cardiovascular risk factors, such as waist circum-
ference, BP and lipid concentrations, and associated with an
increased frequency of diabetes, hypercholesterolemia,
hypertension and cardiovascular disease. These findings are
consistent with reports that high ALP is associated with var-
ious cardiovascular diseases, such as PAD (17), left ventric-
ular hypertrophy (23), secondary cardiac failure and diastolic
dysfunction (24).
There may be a theoretical basis for the association
between ALP and cardiovascular disease. Serum ALP is
known to be higher in obese patients and may play a role in
the mechanisms of adipogenesis (14, 16, 25). ALP appears
to be involved in lipid absorption and intestinal ALP activ-
ities may increase after a high fat meal (26, 27). Thus,
increased ALP may be a marker of an atherogenic diet. ALP
is also known to be negatively correlated with adiponectin
(2), a hormone secreted by adipose tissues that predicts the
development of type 2 diabetes (28) and hypertension (29)
in prospective studies. In a secondary atherosclerotic plaque,
there is vascular calcification (30), which is thought to be
regulated by ALP (31). Emerging evidence from a prospec-
tive epidemiological study has suggested that vitamin D
deficiency is correlated with higher rates of cardiovascular
disease, especially in hypertensive patients (32). It is there-
fore tempting to speculate that vitamin D deficiency, a
surrogate for cardiovascular disease, leads to hyperparathy-
roidism, high bone turnover, and increased ALP activities.
This is a premise that warrants further study.
The JUPITER (Justification for the Use of Statins in Pri-
mary Prevention: An Intervention Trial Evaluating Rosuvas-
tatin) trial showed that people with modest cardiovascular
risk, but with increased CRP, benefited from statin therapy
irrespective of their LDL concentrations (33). It would be of
interest to determine from large randomized trials of statins
if people with increased ALP activity and cardiovascular risk
factors might also benefit from statins.
There are some limitations to our study. The relationship
between ALP and CRP is an association and it is not possible
to conclude that it is causal. Since the data are cross-sec-
tional, we do not know if any changes in CRP immediately
affect ALP activity. ALP is known to be raised in a number
of diseases and the presence of unknown subclinical disease
in participants may have confounded the relationship
between ALP and CRP. The ALP measured in NHANES was
in the serum and the origin of the enzyme is therefore unclear
as ALP is present in many tissues in the body. Expression
of ALP in the heart, vascular tissue, granulocytes or the liver
may be altered in cardiovascular disease, but this needs to
be investigated in further studies.
We cannot determine the potential benefits of an ALP test
for cardiovascular disease at this time. The discriminating
ability of an ALP test must be measured as part of prospec-
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tive studies, with respect to sensitivity and specificity in
order to determine the utility of such a diagnostic tool. Sim-
ilarly, the association between serum ALP and cardiovascular
disease, with respect to the nature and direction of causation
cannot be concluded from the results. Such conclusions
should be drawn from randomized controlled trials of novel
ALP inhibitors.
In conclusion, plasma ALP activity correlated significantly
with plasma CRP concentrations, after controlling for con-
founding variables in a large, nationally representative sam-
ple population. CRP is known to be a good marker of
cardiovascular risk (8), but measuring it requires a specific
and costly test. ALP is a routinely measured liver function
test, and thus does not represent an extra cost. This may
make it an invaluable marker, not only in contemporary and
future research studies, but also in historical and retrospec-
tive studies, and studies performed in developing countries.
Although our results raise the possibility that it could be used
as a marker of cardiovascular risk, further research is needed
to assess the utility of ALP in a panel of markers of cardio-
vascular risk in large cohorts and in diverse ethnic
populations.
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